ACXP Acurx Pharmaceuticals
- 2.170
- +0.050+2.36%
- 2.210
- +0.040+1.84%
Acurx Pharmaceuticals News
Acurx Pharmaceuticals | ARS: Annual Report to Security Holders
Acurx Pharmaceuticals | DEFA14A: Others
Acurx Pharmaceuticals | DEF 14A: Definitive information statements
Acurx Pharmaceuticals | RW: Registration Withdrawal Request
Acurx Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer LUCI DAVID P
Acurx Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Shawah Robert G.
Acurx Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director DELUCCIA ROBERT J
Acurx Pharmaceuticals | FWP: Filing under Securities Act Rules 163/433 of free writing prospectuses
Acurx Pharmaceuticals | S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)
Acurx Pharmaceuticals | 8-K: Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
Acurx Pharmaceuticals | S-1: General form for registration of securities under the Securities Act of 1933
Acurx Pharmaceuticals | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Acurx Pharmaceuticals | 10-K: Annual report
Acurx Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Armistice Capital, LLC(4.99%),Steven Boyd(4.99%)
Acurx Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Sailer Carl
Acurx Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer LUCI DAVID P
Acurx Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director DELUCCIA ROBERT J
Acurx Pharmaceuticals | 8-K: Current report
Acurx Pharmaceuticals | 424B5: Prospectus
Acurx Pharmaceuticals | 8-K: Acurx Pharmaceuticals, Inc. Reports Third Quarter 2023 Results and Provides Business Update
Analysis
Price Target
No Data
